藤龙补中汤联合新辅助化疗治疗低位直肠癌临床研究

目的:探讨藤龙补中汤联合新辅助化疗治疗低位直肠癌的临床疗效。方法:将42例低位直肠癌患者随机分为对照组和治疗组,其中对照组20例,治疗组22例。对照组给予Xelox方案的新辅助化疗,治疗组在新辅助化疗的基础上加服藤龙补中汤治疗,比较两组患者新辅助化疗前后卡氏评分情况、CEA水平、谷丙转氨酶水平和新辅助化疗后的保肛率。结果:治疗组新辅助化疗后卡氏评分显著优于对照组,CEA水平、谷丙转氨酶水平均低于对照组,差异有统计学意义(P0.05);治疗组的保肛率高于对照组,但差异无统计学意义(P0.05)。结论:藤龙补中汤联合新辅助化疗治疗低位直肠癌能显著改善肿瘤患者生存质量,降低肿瘤标记物水平,保护肝脏功能。

Clinical Research of Tenglong Buzhong Tang Combined with Neoadjuvant Chemotherapy in Treating Low Rectal Cancer

Objective:To explore the clinical efficacy of Tenglong Buzhong Tang combined with neoadjuvant chemotherapy in treating low rectal cancer.Methods:42 cases of patients were randomly divided into the treatment group of 22 cases,and the control group of 20 cases.The control group was given Xelox programs neoadjuvant chemotherapy,and the treatment group was treated with Tenglong Buzhong Tang on the basis of neoadjuvant chemotherapy.Compared the KPS grade scores,CEA levels and alanine aminotransferase level of two groups before and after neoadjuvant chemotherapy,and compared the sphincter preservation rate after neoadjuvant chemotherapy.Results:The KPS grade scores on treatment group after neoadjuvant chemotherapy were significantly better than the control group.The CEA levels,and the alanine aminotransferase levels on the treatment group after neoadjuvant chemotherapy were significantly lower than control group after treatment (P ＜ 0.05).The rate of Sphincter preservation of the treatment group greater than the control group,but had no significant difference (P ＞ 0.05).Conclusion:Tenglong Buzhong Tang combined with neoadjuvant chemotherapy in treating low rectal cancer can improve the quality life of tumor patients significantly,lower the levels of tumor markers,protection the liver function.